MINIEYE announced that its cornerstone investor, Horizon Together Holding Ltd., has recently increased its holdings of the company's H shares by 688,200 on the open market. As a wholly-owned subsidiary of Horizon Robotics, Horizon Together maintains in-depth cooperation with Minieye in areas such as intelligent assisted driving. The share increase stems from its optimism about Minieye's long-term business development, and both parties will continue to promote two-way empowerment through technology and resources.
GCL New Energy Holdings Limited (00451.HK) announced that it has entered into a Subscription and Investment Agreement with independent third party Pharos Network Technology Limited. The Company proposes to issue approximately 187 million new shares at a price of HK$1.033 per share, representing about 10.71% of the enlarged share capital. As consideration for the subscription, the Company will receive future equity rights and token purchase warrants valued at approximately US$24.74 million from Pharos, accelerating the exploration of integration between Web3 and the new energy industry.
CLOUDBREAK PHARMA INC. (02592.HK) announced that its indirectly wholly-owned subsidiary, Cloudbreak Biopharma Technology (Guangzhou) Co., Ltd., has received a court notice stating that due to an ongoing arbitration proceeding, approximately RMB 2.55 million in cash in its bank account has been subject to judicial preservation until November 30, 2026. The arbitration involves a claim for unpaid service fees of around US$2.05 million plus related interest.
MINIEYE(02431.HK) will spend HKD 25.8 million to repurchase 1.75 million shares on Jan 7, 2026 .
XIAOMI-W(01810.HK) will spend HKD 148.84 million to repurchase 3.9 million shares on Jan 7, 2026 .
BAIRONG-W(06608.HK) will spend HKD 25.67 million to repurchase 2.05 million shares on Jan 7, 2026 .
MAO GEPING COSMETICS CO., LTD. (01318.HK) announced that it has signed a strategic cooperation framework agreement with L Catterton, a world-leading consumer investment institution. The two parties intend to carry out cooperation in aspects including global market expansion, equity investment, capital optimization, and talent introduction.
China International Capital Corporation Limited (03908.HK) announced that the first tranche of its 2026 publicly issued perpetual subordinated bonds targeting professional investors will be book-built on January 8, 2026. The issuance size shall not exceed RMB 3 billion, the bond is abbreviated as "26 CICC Y1", and the coupon rate inquiry range is set at 1.90%-2.90%.
Jiangsu Guofu Hydrogen Energy Equipment Co., Ltd. (02582.HK) announced that it has entered into a pre-purchase order agreement with its 14%-owned Australian associate company, LineHydrogen (Australia) Pty Ltd, for the Tasmania Hydrogen Energy Project in Australia. The agreement covers a variety of equipment and services such as electrolytic hydrogen production systems and hydrogen refueling stations.
FUDANZHANGJIANG announced that it has entered into an agreement with Ping An Bank to subscribe for a principal-guaranteed floating-income structured deposit product with RMB270 million of its own idle funds. The product has an 83-day term, a maximum annualized return rate of 2.13%, and is rated as medium-low risk. It aims to enhance capital returns while complying with the company’s principles of capital safety and liquidity.
Eurasia Aerosol, a subsidiary of Precious PRECIOUS DRAGON, has entered into a construction agreement with a contractor to carry out the construction and renovation project of its production factory in Guangzhou, with a total investment of RMB34.8 million (approximately HK$38.3 million). Expected to be completed by July 29, 2026, the project will help the company expand production capacity, meet the requirements of environmental regulations, and enhance the competitiveness of its Original Brand Manufacturing (OBM) business.
SHANXI INSTALL announced that its proposed issuance of domestic corporate bonds has obtained the registration approval from the China Securities Regulatory Commission (CSRC). The approval permits the company to publicly issue corporate bonds with a total par value not exceeding RMB1.35 billion to professional investors, with a validity period of 24 months for the approval, during which the company may issue the bonds in installments.
QHD PORT announced that its total throughput in 2025 reached 432.53 million tons, a year-on-year (YoY) increase of 4.48% compared with 414.00 million tons in 2024. The throughput of the company's three major ports all achieved YoY growth, among which Huanghua Port led with a growth rate of 8.04%, while Qinhuangdao Port and Caofeidian Port recorded growth rates of 3.81% and 2.74% respectively.
After obtaining the general mandate from the shareholders' general meeting on November 26, 2025, GF SECannounced on January 6, 2026 that it intends to place 219 million new H-shares at HK$18.15 per share and issue HK$2.15 billion zero-coupon convertible bonds due 2027 with an initial conversion price of HK$19.82 per share. The total funds raised from the two items are expected to be approximately HK$6.113 billion, and the net proceeds are intended to be fully used for capital increase to overseas subsidiaries to support the development of international business. The placed shares account for approximately 12.87% of the existing H-shares. If the convertible bonds are fully converted, approximately 108 million H-shares can be issued, accounting for approximately 6.37% of the existing H-shares. The completion of both issuances is subject to the fulfillment of conditions such as listing approval and filing with the China Securities Regulatory Commission.
HUTCHMED announced that the Phase III stage of the ESLIM-02 study on its Syk inhibitor sostarlimab for the treatment of warm antibody autoimmune hemolytic anemia has met the primary endpoint, namely sustained hemoglobin response during the treatment period from Week 5 to Week 24. The study targets patients who relapsed or were refractory after previous standard treatments. The company plans to submit a new drug application for this indication to the National Medical Products Administration in the first half of 2026. The Phase III study of sostarlimab for the treatment of immune thrombocytopenia has also achieved positive results, and the company similarly plans to resubmit a new drug application for this indication in the first half of 2026.
APEX ACE HLDG (6036), through its indirectly wholly-owned subsidiary Avite International, paid a premium of US$3.5 million (approximately HK$27.3 million) to HSBC Life on January 5, 2026 to purchase a whole life insurance policy for Mr. Li, the executive director and chairman. This key person insurance policy constitutes a discloseable transaction under the listing rules. On the same day, the borrower confirmed its acceptance of a HK$215.8 million revolving trade loan facility provided by HSBC. The financing terms stipulate that if Mr. Li ceases to serve as chairman and chief executive officer, it will constitute a default. The board of directors believes that the policy can provide financial protection for the Group, and the death benefit may be higher than the premium expenditure in the future.
